Iovance Biotherapeutics, Inc.
IOVA
$3.30
$0.247.84%
| Weiss Ratings | IOVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | IOVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | IOVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.33 | |||
| Price History | IOVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -6.78% | |||
| 30-Day Total Return | -22.08% | |||
| 60-Day Total Return | -44.16% | |||
| 90-Day Total Return | -64.59% | |||
| Year to Date Total Return | -57.64% | |||
| 1-Year Total Return | -74.98% | |||
| 2-Year Total Return | -40.00% | |||
| 3-Year Total Return | -80.65% | |||
| 5-Year Total Return | -89.08% | |||
| 52-Week High % Change | -78.50% | |||
| 52-Week Low % Change | 13.33% | |||
| Price | IOVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $14.23 | |||
| 52-Week Low Price | $2.70 | |||
| 52-Week Low Price (Date) | Apr 07, 2025 | |||
| 52-Week High Price (Date) | May 06, 2024 | |||
| Valuation | IOVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.00B | |||
| Enterprise Value | 737.79M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.30 | |||
| Earnings Per Share Growth | -31.46% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 5.69 | |||
| Price/Book (Q) | 1.31 | |||
| Enterprise Value/Revenue (TTM) | 4.50 | |||
| Price | $3.30 | |||
| Enterprise Value/EBITDA (TTM) | -2.04 | |||
| Enterprise Value/EBIT | -1.87 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | IOVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 304.89M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | IOVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | (650) 260-7120 | |||
| Address | 825 Industrial Road San Carlos, CA 94070 | |||
| Website | www.iovance.com | |||
| Country | United States | |||
| Year Founded | 2007 | |||
| Profitability | IOVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -240.92% | |||
| Profit Margin | -226.84% | |||
| Management Effectiveness | IOVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -29.22% | |||
| Return on Equity | -- | |||
| Income Statement | IOVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 164.07M | |||
| Total Revenue (TTM) | 164.07M | |||
| Revenue Per Share | $0.54 | |||
| Gross Profit (TTM) | 40.08M | |||
| EBITDA (TTM) | -362.11M | |||
| EBIT (TTM) | -395.28M | |||
| Net Income (TTM) | -372.18M | |||
| Net Income Avl. to Common (TTM) | -372.18M | |||
| Total Revenue Growth (Q YOY) | 15,189.21% | |||
| Earnings Growth (Q YOY) | 32.50% | |||
| EPS Diluted (TTM) | -1.30 | |||
| EPS Diluted Growth (Q YOY) | 43.33% | |||
| Balance Sheet | IOVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 323.78M | |||
| Cash Per Share (Q) | $1.06 | |||
| Total Current Assets (Q) | 457.02M | |||
| Total Preferred Equity (Q) | 0.00 | |||
| Total Equity (Q) | 710.41M | |||
| Current Ratio (Q) | 3.736 | |||
| Book Value Per Share (Q) | $2.33 | |||
| Total Assets (Q) | 910.43M | |||
| Total Current Liabilities (Q) | 122.34M | |||
| Total Debt (Q) | 58.26M | |||
| Total Liabilities (Q) | 200.02M | |||
| Total Common Equity (Q) | 710.40M | |||
| Cash Flow | IOVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -96.41M | |||
| Cash from Financing (TTM) | 390.66M | |||
| Net Change in Cash (TTM) | -59.27M | |||
| Levered Free Cash Flow (TTM) | -203.22M | |||
| Cash from Operations (TTM) | -352.98M | |||
